Liminal BioSciences Inc. LMNL

Healthcare Biotechnology

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.

NDAQ:LMNL - Post by User

Liminal BioSciences Inc.

Bullboard Posts

Post by Biofinderon May 30, 2018 9:29pm

311 Views

Post# 28102771

Ryplazim PBI-4050 - The OneTwo Punch for IPF Fibrosis

https://pulmonaryfibrosisnews.com/2018/05/29/prometic-pbi-4050-ryplazim-prevent-lung-fibrosis-phase-2-3-preclinical-data/

“The study showed that under-the-skin injections of Ryplazim every three days significantly reduced collagen deposition in the inflamed areas of the lungs of mice with induced pulmonary fibrosis. In contrast, treatment with Esbriet or Ofev alone did not have a significant effect. Nevertheless, when these approved therapies were combined with Ryplazim, a significant reduction in the percentage of collagen was reported.”

Bullboard Posts

WINNERS of the COP 29: Siemens Energy, Plug Power, dynaCERT!